23/120
1.0 / 5 stars
All 120 Win/Lose results shown below
RLMD Roast Me summary
RELMADA THERAPEUTICS, INC. (RLMD). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseRLMD / S&P -0.57% / 15.20% |
LoseRLMD / S&P RLMD unavailable / 15.00% |
LoseRLMD / S&P RLMD unavailable / 50.40% |
| 2026-Q11/3 |
WinRLMD / S&P 44.10% / -4.33% |
LoseRLMD / S&P RLMD unavailable / 11.30% |
LoseRLMD / S&P RLMD unavailable / 27.70% |
| 2025-Q41/3 |
WinRLMD / S&P 140.30% / 2.65% |
LoseRLMD / S&P RLMD unavailable / 9.00% |
LoseRLMD / S&P RLMD unavailable / 13.40% |
| 2025-Q31/3 |
WinRLMD / S&P 235.00% / 8.12% |
LoseRLMD / S&P RLMD unavailable / 4.61% |
LoseRLMD / S&P RLMD unavailable / 13.45% |
| 2025-Q21/3 |
WinRLMD / S&P 122.22% / 10.94% |
LoseRLMD / S&P RLMD unavailable / 4.83% |
LoseRLMD / S&P RLMD unavailable / 10.63% |
| 2025-Q10/3 |
LoseRLMD / S&P -48.08% / -4.27% |
LoseRLMD / S&P RLMD unavailable / 4.98% |
LoseRLMD / S&P RLMD unavailable / 10.57% |
| 2024-Q40/3 |
LoseRLMD / S&P -83.95% / 2.41% |
LoseRLMD / S&P RLMD unavailable / 5.25% |
LoseRLMD / S&P RLMD unavailable / 6.15% |
| 2024-Q31/3 |
WinRLMD / S&P 8.00% / 5.89% |
LoseRLMD / S&P RLMD unavailable / 5.89% |
LoseRLMD / S&P RLMD unavailable / 6.11% |
| 2024-Q20/3 |
LoseRLMD / S&P -35.48% / 4.28% |
LoseRLMD / S&P RLMD unavailable / 5.38% |
LoseRLMD / S&P RLMD unavailable / 5.12% |
| 2024-Q11/3 |
WinRLMD / S&P 12.32% / 10.56% |
LoseRLMD / S&P RLMD unavailable / 5.71% |
LoseRLMD / S&P RLMD unavailable / 5.59% |
| 2023-Q41/3 |
WinRLMD / S&P 38.00% / 11.69% |
LoseRLMD / S&P RLMD unavailable / 6.81% |
LoseRLMD / S&P RLMD unavailable / 7.78% |
| 2023-Q31/3 |
WinRLMD / S&P 21.95% / -3.27% |
LoseRLMD / S&P RLMD unavailable / 7.52% |
LoseRLMD / S&P RLMD unavailable / -5.03% |
| 2023-Q21/3 |
WinRLMD / S&P 8.85% / 8.74% |
LoseRLMD / S&P RLMD unavailable / 9.50% |
LoseRLMD / S&P RLMD unavailable / -8.57% |
| 2023-Q10/3 |
LoseRLMD / S&P -35.24% / 7.50% |
LoseRLMD / S&P RLMD unavailable / 10.77% |
LoseRLMD / S&P RLMD unavailable / -15.69% |
| 2022-Q40/3 |
LoseRLMD / S&P -90.57% / 7.56% |
LoseRLMD / S&P RLMD unavailable / 11.88% |
LoseRLMD / S&P RLMD unavailable / -17.99% |
| 2022-Q31/3 |
WinRLMD / S&P 94.94% / -4.88% |
LoseRLMD / S&P RLMD unavailable / 13.47% |
LoseRLMD / S&P RLMD unavailable / -1.41% |
| 2022-Q20/3 |
LoseRLMD / S&P -29.64% / -16.10% |
LoseRLMD / S&P RLMD unavailable / 13.71% |
LoseRLMD / S&P RLMD unavailable / 11.04% |
| 2022-Q11/3 |
WinRLMD / S&P 19.80% / -4.60% |
LoseRLMD / S&P RLMD unavailable / 15.97% |
LoseRLMD / S&P RLMD unavailable / 42.23% |
| 2021-Q40/3 |
LoseRLMD / S&P -14.04% / 11.03% |
LoseRLMD / S&P RLMD unavailable / 15.00% |
LoseRLMD / S&P RLMD unavailable / 96.40% |
| 2021-Q30/3 |
LoseRLMD / S&P -18.12% / 0.58% |
LoseRLMD / S&P RLMD unavailable / 10.77% |
LoseRLMD / S&P RLMD unavailable / 69.42% |
| 2021-Q20/3 |
LoseRLMD / S&P -9.09% / 8.55% |
LoseRLMD / S&P RLMD unavailable / 6.58% |
LoseRLMD / S&P RLMD unavailable / 51.81% |
| 2021-Q11/3 |
WinRLMD / S&P 9.79% / 6.17% |
LoseRLMD / S&P RLMD unavailable / -1.06% |
LoseRLMD / S&P RLMD unavailable / 7.39% |
| 2020-Q40/3 |
LoseRLMD / S&P -14.75% / 12.15% |
LoseRLMD / S&P RLMD unavailable / -3.72% |
LoseRLMD / S&P RLMD unavailable / -33.42% |
| 2020-Q30/3 |
LoseRLMD / S&P -15.93% / 8.93% |
LoseRLMD / S&P RLMD unavailable / -2.04% |
LoseRLMD / S&P RLMD unavailable / -27.10% |
| 2020-Q21/3 |
WinRLMD / S&P 31.19% / 20.54% |
LoseRLMD / S&P RLMD unavailable / -0.46% |
LoseRLMD / S&P RLMD unavailable / -27.11% |
| 2020-Q11/3 |
WinRLMD / S&P -12.54% / -19.60% |
LoseRLMD / S&P RLMD unavailable / 3.47% |
LoseRLMD / S&P RLMD unavailable / -14.75% |
| 2019-Q41/3 |
WinRLMD / S&P 280.49% / 9.07% |
LoseRLMD / S&P RLMD unavailable / 5.36% |
LoseRLMD / S&P RLMD unavailable / 2.99% |
| 2019-Q31/3 |
WinRLMD / S&P 38.14% / 1.70% |
LoseRLMD / S&P RLMD unavailable / 5.02% |
LoseRLMD / S&P RLMD unavailable / 0.21% |
| 2019-Q21/3 |
WinRLMD / S&P 4.80% / 4.30% |
LoseRLMD / S&P RLMD unavailable / 6.64% |
LoseRLMD / S&P RLMD unavailable / 8.65% |
| 2019-Q11/3 |
WinRLMD / S&P 53.91% / 13.65% |
LoseRLMD / S&P RLMD unavailable / 8.12% |
LoseRLMD / S&P RLMD unavailable / 14.29% |
| 2018-Q41/3 |
WinRLMD / S&P 2.68% / -13.52% |
LoseRLMD / S&P RLMD unavailable / 9.05% |
LoseRLMD / S&P RLMD unavailable / 18.23% |
| 2018-Q31/3 |
WinRLMD / S&P 10.89% / 7.71% |
LoseRLMD / S&P RLMD unavailable / 10.21% |
LoseRLMD / S&P RLMD unavailable / 19.06% |
| 2018-Q21/3 |
WinRLMD / S&P 13.48% / 3.43% |
LoseRLMD / S&P RLMD unavailable / 9.03% |
LoseRLMD / S&P RLMD unavailable / 14.46% |
| 2018-Q11/3 |
WinRLMD / S&P 18.67% / -0.76% |
LoseRLMD / S&P RLMD unavailable / 7.68% |
LoseRLMD / S&P RLMD unavailable / 12.46% |
| 2017-Q40/3 |
LoseRLMD / S&P -21.05% / 6.64% |
LoseRLMD / S&P RLMD unavailable / 7.03% |
LoseRLMD / S&P RLMD unavailable / 13.82% |
| 2017-Q31/3 |
WinRLMD / S&P 15.85% / 4.48% |
LoseRLMD / S&P RLMD unavailable / 5.68% |
LoseRLMD / S&P RLMD unavailable / 17.57% |
| 2017-Q20/3 |
LoseRLMD / S&P -8.89% / 3.09% |
LoseRLMD / S&P RLMD unavailable / 4.83% |
LoseRLMD / S&P RLMD unavailable / 17.74% |
| 2017-Q10/3 |
LoseRLMD / S&P -17.43% / 6.07% |
LoseRLMD / S&P RLMD unavailable / 3.67% |
LoseRLMD / S&P RLMD unavailable / 13.32% |
| 2016-Q40/3 |
LoseRLMD / S&P -25.85% / 3.82% |
LoseRLMD / S&P RLMD unavailable / 2.09% |
LoseRLMD / S&P RLMD unavailable / 7.05% |
| 2016-Q30/3 |
LoseRLMD / S&P -35.53% / 3.85% |
LoseRLMD / S&P RLMD unavailable / 0.20% |
LoseRLMD / S&P RLMD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | RLMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 286.61% | 20.78% |
| Annualized return | 286.61% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | RLMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -81.99% | 83.14% |
| Annualized return | -29.02% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | RLMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -25.86% | 319.30% |
| Annualized return | -2.95% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |